Noble Hospital Pvt. Ltd.

153 Magarpatta city Road, Hadapsar, Pune-411013, Maharashtra, India.

For following Study PI & CO-I: Hand-Foot Skin Reaction(OQL011),Metastatic Breast Cancer (MBC),Metastatic disease (CRD-49)

PI Name: - Dr. Minish Jain (Medical Oncologist)

For Following study PI & CO-I:Acute Myeloid Leukemia (AML)

PI Name: - Dr. Abhijit Baheti(Haematologist)

Below Mentioned Study Ongoing on Noble Hospital Pvt. Ltd. Pune.

Study Title

1. A multicenter, open-label, balanced, randomized, two-treatment, three-period, three-sequence, partial replicate, single dose, cross-over bioequivalence study of Azacitidine film-coated tablets 300 mg and ONUREGTM (Azacitidine) film-coated tablets 300 mg in adult patients with acute myeloid leukemia (AML) under fasting condition.

2. A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients.

3. A Multicenter, Double-Blind, Randomized, Parallel-Group, Active-Controlled, Phase III, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Metastatic Breast Cancer (MBC)

4. A multicentre, open label, randomized, balanced, two treatment, two-sequence, four period, replicate crossover, single dose, bioequivalence study of paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial, manufactured by M/s MSN Lab Pvt. Ltd., India for M/s Cipla Ltd., India with ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/vial by Celgene Corporation, USA in breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.